The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery
Status: | Recruiting |
---|---|
Conditions: | Sinusitis |
Therapuetic Areas: | Otolaryngology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | December 2015 |
End Date: | February 2016 |
Contact: | B.Todd Schaeffer, MD |
Email: | TSchaeffer@entandallergy.com |
Phone: | 516-775-2800 |
The PIO III Study: In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery
Report on the technical feasibility and outcomes of in-office placement of PROPEL or PROPEL
mini implants immediately following ethmoid sinus surgery
mini implants immediately following ethmoid sinus surgery
The PROPEL mometasone furoate-releasing implant (Intersect ENT, Menlo Park, CA) is the first
FDA-approved device for reducing the need for post-operative interventions by maintaining
patency and delivering steroid medication directly into the ethmoid cavity following
surgery. Five recently published clinical trials have demonstrated that the mometasone
furoate-releasing implant placed in the hospital operating room or in the office setting
produces statistically significant reductions in inflammation, polyp formation, and
postoperative adhesions. In addition, the implant has been found to significantly reduce the
need for postoperative prescription of oral steroids and to decrease the frequency of
postoperative lysis of adhesions. Minimal adverse effects were reported in these trials.
FDA-approved device for reducing the need for post-operative interventions by maintaining
patency and delivering steroid medication directly into the ethmoid cavity following
surgery. Five recently published clinical trials have demonstrated that the mometasone
furoate-releasing implant placed in the hospital operating room or in the office setting
produces statistically significant reductions in inflammation, polyp formation, and
postoperative adhesions. In addition, the implant has been found to significantly reduce the
need for postoperative prescription of oral steroids and to decrease the frequency of
postoperative lysis of adhesions. Minimal adverse effects were reported in these trials.
Inclusion Criteria:
- Age ≥ 18 years
- Confirmed diagnosis of CRS (Chronic Rhinosinusitis) based on the 2015 Clinical
Practice Guideline for Adult Sinusitis [6]
- Prior ESS (Ethmoid Sinus Surgery) including bilateral total ethmoidectomy at least 90
days prior to being considered for this study
- Planned ESS includes bilateral polypectomy
- ESS including bilateral polypectomy has been successfully completed without
significant complication that, in the opinion of the investigator, would confound
study results, and the patient's anatomy remains amenable to implant placement.
- Bilateral polyposis (minimum grade 2 on each side) originating from the ethmoid sinus
region
- Complaints of at least 2 of the 5 hallmark symptoms of chronic sinusitis: nasal
obstruction/congestion, post-nasal discharge, thick nasal discharge, facial
pain/pressure, or decreased sense of smell.
- Minimum symptom threshold (Nasal Obstruction/Congestion minimum score of 2 on scale
from 0 to 3)
- Failed medical therapy within the preceding 12 months
Exclusion Criteria:
- Not able to give consent
- Oral-steroid dependent condition
- Allergy or intolerance to corticosteroids
- Clinical evidence of bacterial sinusitis or invasive fungal sinusitis
- Pregnancy
We found this trial at
4
sites
Port Jefferson, New York 11777
Principal Investigator: John Sugrue, MD
Phone: 845-562-5941
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: B.Todd Schaeffer, MD
Phone: 845-562-5941
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Roheen Raithatha, MD
Phone: 845-562-5941
Click here to add this to my saved trials
White Plains, New York 10601
Principal Investigator: Daniel Gold, MD
Phone: 845-562-5941
Click here to add this to my saved trials